Search

Your search keyword '"Rosenberger, Peter"' showing total 905 results
Start Over Author "Rosenberger, Peter" Publication Year Range Last 50 years
905 results on '"Rosenberger, Peter"'

3. Epidemiology of surgery associated acute kidney injury (EPIS-AKI): a prospective international observational multi-center clinical study

Author

Zarbock, Alexander, Weiss, Raphael, Albert, Felix, Rutledge, Kristen, Kellum, John A., Bellomo, Rinaldo, Grigoryev, Evgeny, Candela-Toha, Angel M., Demir, Z. Aslı, Legros, Vincent, Rosenberger, Peter, Galán Menéndez, Patricia, Garcia Alvarez, Mercedes, Peng, Ke, Léger, Maxime, Khalel, Wegdan, Orhan-Sungur, Mukadder, and Meersch, Melanie

Published
2023
Full Text
View/download PDF

5. Semaphorin 7A coordinates neutrophil response during pulmonary inflammation and sepsis

Author

Granja, Tiago, Köhler, David, Tang, Linyan, Burkard, Philipp, Eggstein, Claudia, Hemmen, Katherina, Heinze, Katrin G., Heck-Swain, Ka-Lin, Koeppen, Michael, Günther, Sven, Blaha, Maximilian, Magunia, Harry, Bamberg, Maximilian, Konrad, Franziska, Ngamsri, Kristian-Christos, Fuhr, Anika, Keller, Marius, Bernard, Alice M., Haeberle, Helene A., Bakchoul, Tamam, Zarbock, Alexander, Nieswandt, Bernhard, and Rosenberger, Peter

Published
2024
Full Text
View/download PDF

6. Statistical analysis plan for the biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2) study: An international randomised controlled multicentre trial

Author

Wempe, Carola, Storck, Michael, Brix, Tobias, Strauss, Christian, Sadjadi, Mahan, Weiss, Raphael, Booke, Hendrik, Loomann, Lisa, Amini, Wida, Meschede, Dana, Göbel, Ulrich, Haaker, Jan Gerrit, Brenner, Thorsten, Espeter, Florian, Rahmel, Tim, Adamzik, Michael, Brandenburger, Timo, Putensen, Christian, Bode, Christian, Kruse, Philippe, Wild, Lennart, Rosenberger, Peter, Bernard, Alice, Jung-König, Mona, Larmann, Jan, Reutershan, Jörg, Arndt, Christian, Vojnar, Benjamin, Spieth, Peter M., Schneider, Antoine, Monard, Céline, Mura, Benedetta, Villa, Gianluca, Laici, Cristiana, Siniscalchi, Antonio, Capozzi, Chiara, Sita, Marco, Cattin, Lucia, de Rosa, Silvia, Spadaro, Savino, Franco, D'Arcangelo Benito, Ostermann, Marlies, Gossage, James, Verzelloni, Alessandra, Scaramuzzi, Marco, Glass, Adam, Silversides, Jon, Lonsdale, Elliot, Forni, Lui G., Haider, Syeda, Rossiter, Adam, Welters, Ingeborg, Hoste, Eric, Hollmann, Markus W., Ripollés-Melchor, Javier, Fernández-Valdes-Bango, Paula, Parise-Roux, Diego, Martin González, Maria Carmen, Bathal, Irene Romero, Jáuregui, Maider Puyada, Navarro-Perez, Rosalía, De Soto, Inés, García-Álvarez, Raquel, Sánchez, Elena Murcia, Suarez-de-la-Rica, Alejandro, Lalande, Robin, von Groote, Thilo, Danzer, Moritz Fabian, Meersch, Melanie, Zarbock, Alexander, and Gerß, Joachim

Published
2024
Full Text
View/download PDF

9. Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial

Author

Haeberle, Helene A., Calov, Stefanie, Martus, Peter, Serna-Higuita, Lina Maria, Koeppen, Michael, Goll, Almuth, Bernard, Alice, Zarbock, Alexander, Meersch, Melanie, Weiss, Raphael, Mehrländer, Martin, Marx, Gernot, Putensen, Christian, Bakchoul, Tamam, Magunia, Harry, Nieswandt, Bernhard, Mirakaj, Valbona, and Rosenberger, Peter

Published
2023
Full Text
View/download PDF

10. Uterine allograft removal by total laparoscopic hysterectomy after successful cesarean delivery in a living-donor uterus recipient with uterovaginal agenesis (MRKHS)

Author

Brucker, Sara Yvonne, Krämer, Bernhard, Abele, Harald, Henes, Melanie, Hoopmann, Markus, Schöller, Dorit, Königsrainer, Alfred, Bösmüller, Hans, Nikolaou, Konstantin, Krumm, Patrick, Rosenberger, Peter, Heim, Eckhard, Amend, Bastian, Rausch, Steffen, Althaus, Karina, Bakchoul, Tamam, Guthoff, Martina, Heyne, Nils, Nadalin, Silvio, and Rall, Kristin Katharina

Published
2023
Full Text
View/download PDF

14. Feasibility Assessment of a Biomarker-Guided Kidney-Sparing Sepsis Bundle: The Limiting Acute Kidney Injury Progression In Sepsis Trial

Author

Gómez, Hernando, Zarbock, Alexander, Pastores, Stephen M., Frendl, Gyorgy, Bercker, Sven, Asfar, Pierre, Conrad, Steven A., Creteur, Jaques, Miner, James, Mira, Jean Paul, Motsch, Johan, Quenot, Jean-Pierre, Rimmelé, Thomas, Rosenberger, Peter, Vinsonneau, Christophe, Birch, Bob, Heskia, Fabienne, Textoris, Julien, Molinari, Luca, Guzzi, Louis M., Ronco, Claudio, and Kellum, John A.

Published
2023
Full Text
View/download PDF

15. Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation

Author

Stegner, David, Göb, Vanessa, Krenzlin, Viola, Beck, Sarah, Hemmen, Katherina, Schuhmann, Michael K., Schörg, Barbara F., Hackenbroch, Christian, May, Frauke, Burkard, Philipp, Pinnecker, Jürgen, Zernecke, Alma, Rosenberger, Peter, Greinacher, Andreas, Pichler, Bernd J., Heinze, Katrin G., Stoll, Guido, and Nieswandt, Bernhard

Published
2022
Full Text
View/download PDF

16. Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study

Author

Rahmel, Tim, Kraft, Felix, Haberl, Helge, Achtzehn, Ute, Brandenburger, Timo, Neb, Holger, Jarczak, Dominik, Dietrich, Maximilian, Magunia, Harry, Zimmer, Frieda, Basten, Jale, Landgraf, Claudia, Koch, Thea, Zacharowski, Kai, Weigand, Markus A., Rosenberger, Peter, Ullrich, Roman, Meybohm, Patrick, Nierhaus, Axel, Kindgen-Milles, Detlef, Timmesfeld, Nina, and Adamzik, Michael

Published
2022
Full Text
View/download PDF

17. Key characteristics impacting survival of COVID-19 extracorporeal membrane oxygenation

Author

Herrmann, Johannes, Lotz, Christopher, Karagiannidis, Christian, Weber-Carstens, Steffen, Kluge, Stefan, Putensen, Christian, Wehrfritz, Andreas, Schmidt, Karsten, Ellerkmann, Richard K., Oswald, Daniel, Lotz, Gösta, Zotzmann, Viviane, Moerer, Onnen, Kühn, Christian, Kochanek, Matthias, Muellenbach, Ralf, Gaertner, Matthias, Fichtner, Falk, Brettner, Florian, Findeisen, Michael, Heim, Markus, Lahmer, Tobias, Rosenow, Felix, Haake, Nils, Lepper, Philipp M., Rosenberger, Peter, Braune, Stephan, Kohls, Mirjam, Heuschmann, Peter, and Meybohm, Patrick

Published
2022
Full Text
View/download PDF

19. Plexin C1 influences immune response to intracellular LPS and survival in murine sepsis.

Author

Bernard, Alice, Eggstein, Claudia, Tang, Linyan, Keller, Marius, Körner, Andreas, Mirakaj, Valbona, and Rosenberger, Peter

Subjects
ADENYLATE cyclase, CASPASES, PROTEIN kinases, GRAM-negative bacteria, SEPSIS
Abstract

Background: Intracellular sensing of lipopolysaccharide (LPS) is essential for the immune response against gram-negative bacteria and results in activation of caspase-11 and pyroptotic cell death with fatal consequences in sepsis. We found the neuronal guidance receptor plexin C1 (PLXNC1) influences the intracellular response to LPS. Methods: We employed a murine model of sepsis via cecal ligation and binding (CLP), using PLXNC1-/- mice and littermate controls, and additionally transfected murine bone-marrow-derived macrophages (BMDMs) from both genotypes with LPS to achieve activation of the noncanonical inflammasome ex vivo. Additionally, we transfected the PLXNC1 ligand SL4c-d in vivo and ex vivo to examine its effect on intracellular LPS response. Results: We found the neuronal guidance receptor PLXNC1 dampens the intracellular response to LPS by interacting with adenylate cyclase 4 (ADCY4) and protein kinase A activity, which in turn diminishes caspase-11 expression. The absence of PLXNC1 results in excessive inflammation marked by increased cytokine release, increased secondary organ injury and reduced sepsis survival in a murine sepsis model induced by CLP. Notably, administration of SL4c-d—peptide ligand of PLXNC1—reduces the inflammatory response during CLP-induced sepsis and improves survival. Conclusions: These results elucidate a previously unknown mechanism for PLXNC1 suppressing excessive noncanonical inflammasome activity and offer a new potential target for treatment of sepsis with its detrimental effects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients

Author

Korper, Sixten, Gruner, Beate, Zickler, Daniel, Wiesmann, Thomas, Wuchter, Patrick, Blasczyk, Rainer, Zacharowski, Kai, Spieth, Peter, Tonn, Torsten, Rosenberger, Peter, Paul, Gregor, Pilch, Jan, Schwable, Joachim, Bakchoul, Tamam, Thiele, Thomas, Knorlein, Julian, Dollinger, Matthias M., Krebs, Jorg, Bentz, Martin, Corman, Victor M., Kilalic, Dzenan, Schmidtke-Schrezenmeier, Gerlinde, Lepper, Philipp M., Ernst, Lucas, Wulf, Hinnerk, Ulrich, Alexandra, Weiss, Manfred, Kruse, Jan Matthias, Burkhardt, Thomas, Muller, Rebecca, Kluter, Harald, Schmidt, Michael, Jahrsdorfer, Bernd, Lotfi, Ramin, Rojewski, Markus, Appl, Thomas, Mayer, Benjamin, Schnecko, Philipp, Seifried, Erhard, and Schrezenmeier, Hubert

Subjects
Quality of life -- Health aspects, Health care industry
Abstract

BACKGROUND. Results of many randomized trials on COVID-19 convalescent plasma (CCP) have been reported, but information on long-term outcome after CCP treatment is limited. The objectives of this extended observation of the randomized CAPSID trial are to assess long-term outcome and disease burden in patients initially treated with or without CCP. METHODS. Of 105 randomized patients, 50 participated in the extended observation. Quality of life (QoL) was assessed by questionnaires and a structured interview. CCP donors (n = 113) with asymptomatic to moderate COVID-19 were included as a reference group. RESULTS. The median follow-up of patients was 396 days, and the estimated 1-year survival was 78.7% in the CCP group and 60.2% in the control (P = 0.08). The subgroup treated with a higher cumulative amount of neutralizing antibodies showed a better 1-year survival compared with the control group (91.5% versus 60.2%, P = 0.01). Medical events and QoL assessments showed a consistent trend for better results in the CCP group without reaching statistical significance. There was no difference in the increase in neutralizing antibodies after vaccination between the CCP and control groups. CONCLUSION. The trial demonstrated a trend toward better outcome in the CCP group without reaching statistical significance. A predefined subgroup analysis showed a significantly better outcome (long-term survival, time to discharge from ICU, and time to hospital discharge) among those who received a higher amount of neutralizing antibodies compared with the control group. A substantial long-term disease burden remains after severe COVID-19. TRIAL REGISTRATION. EudraCT 2020-001310-38 and ClinicalTrials.gov NCT04433910. FUNDING. Bundesministerium fur Gesundheit (German Federal Ministry of Health)., Introduction The use of COVID-19 convalescent plasma (CCP) from patients recovered from a SARS-CoV-2 infection was evaluated in many randomized trials during the pandemic (1-21). The trials were heterogeneous in [...]

Published
2022
Full Text
View/download PDF

23. Explainable Boosting Machine approach identifies risk factors for acute renal failure.

Author

Körner, Andreas, Sailer, Benjamin, Sari-Yavuz, Sibel, Haeberle, Helene A., Mirakaj, Valbona, Bernard, Alice, Rosenberger, Peter, and Koeppen, Michael

Subjects
ACUTE kidney failure, MACHINE learning, CENTRAL venous pressure, CHRONIC kidney failure, INTENSIVE care units, ARRHYTHMIA, HEART failure
Abstract

Background: Risk stratification and outcome prediction are crucial for intensive care resource planning. In addressing the large data sets of intensive care unit (ICU) patients, we employed the Explainable Boosting Machine (EBM), a novel machine learning model, to identify determinants of acute kidney injury (AKI) in these patients. AKI significantly impacts outcomes in the critically ill. Methods: An analysis of 3572 ICU patients was conducted. Variables such as average central venous pressure (CVP), mean arterial pressure (MAP), age, gender, and comorbidities were examined. This analysis combined traditional statistical methods with the EBM to gain a detailed understanding of AKI risk factors. Results: Our analysis revealed chronic kidney disease, heart failure, arrhythmias, liver disease, and anemia as significant comorbidities influencing AKI risk, with liver disease and anemia being particularly impactful. Surgical factors were also key; lower GI surgery heightened AKI risk, while neurosurgery was associated with a reduced risk. EBM identified four crucial variables affecting AKI prediction: anemia, liver disease, and average CVP increased AKI risk, whereas neurosurgery decreased it. Age was a progressive risk factor, with risk escalating after the age of 50 years. Hemodynamic instability, marked by a MAP below 65 mmHg, was strongly linked to AKI, showcasing a threshold effect at 60 mmHg. Intriguingly, average CVP was a significant predictor, with a critical threshold at 10.7 mmHg. Conclusion: Using an Explainable Boosting Machine enhance the precision in AKI risk factors in ICU patients, providing a more nuanced understanding of known AKI risks. This approach allows for refined predictive modeling of AKI, effectively overcoming the limitations of traditional statistical models. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial: GENIUS—Gelatine use in ICU and sepsis

Author

Marx, Gernot, Zacharowski, Kai, Ichai, Carole, Asehnoune, Karim, Černý, Vladimír, Dembinski, Rolf, Ferrer Roca, Ricard, Fries, Dietmar, Molnar, Zsolt, Rosenberger, Peter, Sanchez-Sanchez, Manuel, Schürholz, Tobias, Dehnhardt, Tamara, Schmier, Sonja, von Kleist, Elke, Brauer, Ute, and Simon, Tim-Philipp

Published
2021
Full Text
View/download PDF

28. Machine learning identifies ICU outcome predictors in a multicenter COVID-19 cohort

Author

Magunia, Harry, Lederer, Simone, Verbuecheln, Raphael, Gilot, Bryant Joseph, Koeppen, Michael, Haeberle, Helene A., Mirakaj, Valbona, Hofmann, Pascal, Marx, Gernot, Bickenbach, Johannes, Nohe, Boris, Lay, Michael, Spies, Claudia, Edel, Andreas, Schiefenhövel, Fridtjof, Rahmel, Tim, Putensen, Christian, Sellmann, Timur, Koch, Thea, Brandenburger, Timo, Kindgen-Milles, Detlef, Brenner, Thorsten, Berger, Marc, Zacharowski, Kai, Adam, Elisabeth, Posch, Matthias, Moerer, Onnen, Scheer, Christian S., Sedding, Daniel, Weigand, Markus A., Fichtner, Falk, Nau, Carla, Prätsch, Florian, Wiesmann, Thomas, Koch, Christian, Schneider, Gerhard, Lahmer, Tobias, Straub, Andreas, Meiser, Andreas, Weiss, Manfred, Jungwirth, Bettina, Wappler, Frank, Meybohm, Patrick, Herrmann, Johannes, Malek, Nisar, Kohlbacher, Oliver, Biergans, Stephanie, and Rosenberger, Peter

Published
2021
Full Text
View/download PDF

34. Development of chronic kidney disease after major surgery

Author

Meersch, Melanie, primary, Weiss, Raphael, additional, Strauß, Christian, additional, Albert, Felix, additional, booke, Hendrik, additional, Forni, Lui, additional, Pittet, Jean-Francois, additional, Kellum, John A., additional, Rosner, Mitchell, additional, Mehta, Ravindra, additional, Bellomo, Rinaldo, additional, Rosenberger, Peter, additional, and Zarbock, Alexander, additional

Published
2023
Full Text
View/download PDF

40. Immediate increase of cardiac output after percutaneous mitral valve repair (PMVR) determined by echocardiographic and invasive parameters: Patzelt: Increase of cardiac output after PMVR

Author

Patzelt, Johannes, Zhang, Yingying, Magunia, Harry, Jorbenadze, Rezo, Droppa, Michal, Ulrich, Miriam, Cai, Shanglang, Lausberg, Henning, Walker, Tobias, Wengenmayer, Tobias, Rosenberger, Peter, Schreieck, Juergen, Seizer, Peter, Gawaz, Meinrad, and Langer, Harald F.

Published
2017
Full Text
View/download PDF

46. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19

Author

Korper, Sixten, Weiss, Manfred, Zickler, Daniel, Wiesmann, Thomas, Zacharowski, Kai, Corman, Victor M., Gruner, Beate, Ernst, Lucas, Spieth, Peter, Lepper, Philipp M., Bentz, Martin, Zinn, Sebastian, Paul, Gregor, Kalbhenn, Johannes, Dollinger, Matthias M., Rosenberger, Peter, Kirschning, Thomas, Thiele, Thomas, Appl, Thomas, Mayer, Benjamin, Schmidt, Michael, Drosten, Christian, Wulf, Hinnerk, Kruse, Jan Matthias, Jungwirth, Bettina, Seifried, Erhard, and Schrezenmeier, Hubert

Subjects
Hospital patients -- Care and treatment, Health care industry
Abstract

BACKGROUND. COVID-19 convalescent plasma (CCP) has been considered a treatment option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring respiratory support or intensive care treatment. METHODS. Patients (n = 105) were randomized 1:1 to either receive standard treatment and 3 units of CCP or standard treatment alone. Control group patients with progress on day 14 could cross over to the CCP group. The primary outcome was a dichotomous composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21. RESULTS. The primary outcome occurred in 43.4% of patients in the CCP group and 32.7% in the control group (P = 0.32). The median time to clinical improvement was 26 days in the CCP group and 66 days in the control group (P = 0.27). The median time to discharge from the hospital was 31 days in the CCP group and 51 days in the control group (P = 0.24). In the subgroup that received a higher cumulative amount of neutralizing antibodies, the primary outcome occurred in 56.0% of the patients (vs. 32.1%), with significantly shorter intervals to clinical improvement (20 vs. 66 days, P< 0.05) and to hospital discharge (21 vs. 51 days, P = 0.03) and better survival (day-60 probability of survival 91.6% vs. 68.1%, P = 0.02) in comparison with the control group. CONCLUSION. CCP added to standard treatment was not associated with a significant improvement in the primary and secondary outcomes. A predefined subgroup analysis showed a significant benefit of CCP among patients who received a larger amount of neutralizing antibodies. TRIAL REGISTRATION. ClinicalTrials.gov NCT04433910. FUNDING. Bundesministerium fur Gesundheit (German Federal Ministry of Health): ZMVI1-2520COR802., Introduction COVID-19 convalescent plasma (CCP) from patients who have recovered from a SARS-CoV-2 infection has become one of the treatment options for severe COVID-19 (1, 2). It has been broadly [...]

Published
2021
Full Text
View/download PDF

50. Selecting living donors for uterus transplantation: lessons learned from two transplantations resulting in menstrual functionality and another attempt, aborted after organ retrieval

Author

Brucker, Sara Y., Brännström, Mats, Taran, Florin-Andrei, Nadalin, Silvio, Königsrainer, Alfred, Rall, Katharina, Schöller, Dorit, Henes, Melanie, Bösmüller, Hans, Fend, Falko, Nikolaou, Konstatin, Notohamiprodjo, Mike, Rosenberger, Peter, Grasshoff, Christian, Heim, Eckhard, Krämer, Bernhard, Reisenauer, Christl, Hoopmann, Markus, Kagan, Karl-Oliver, Dahm-Kähler, Pernilla, Kvarnström, Niclas, and Wallwiener, Diethelm

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results